Biosoft aims to become a conductor between fundamental science and services. It helps business representatives to find appropriate scientific partners.



Biosoft aims to put on stream fundamental science problems that phramaceutical and other lifesciences companies are forced to deal with in order to get a desired result.



The BioUML platform is certified and intellectual rights on it totally belong to the Biosoft company



Biosoft is totally responsible for the quality of all of the services it provides.


Top management

Our top management team unites experts in science and administration, that's why Biosoft is developing quickly and efficiently.


Scientific advisers

Biosoft has collected a team of real experts to grant you top quality scientific services.



The workflow system "From genome to target" is coming up this summer

Track the news on our web site as we have almost started the countdown to the very first public release of our workflow system "From genome to target" for automatized search of new therapeutic targets.

6 June 2017
Biosoft is opening a new office in Skolkovo Technopark

Come and join us on the grand opening of Biosoft's new office in Skolkovo Technopark on April 21st! You will find interesting lectures on bioinformatics, workshops and a hakaton on search for personalized biomarkers and drug targets on real patient's data.

5 April 2017
Webinar on discovery of new biomarkers and drug targets

Join us on April 13th if you are interested in molecular medicine and drug development, as we are going to give a webinar on the basic approach for searching for new drug targets and biomarkers.

5 April 2017


The Biosoft company was found in 2008 by Alexander Kel and Fedor Kolpakov with guidance of Institute of Systems Biology, Novosibirsk. The founders of Biosoft at that time had one main idea they wanted to bring to life: they wanted to put on stream the solution of a fundamental scientific problem all pharmaceutical companies had to deal with: the verification and validation of a therapeutic target and compound. This aim brought Alexander and Fedor to understanding of necessity in development of a unified information platform for biomedical data analysis. Fedor has already been working on a prototype of such platform from 2003, so in a relatively short time a commercial version of BIO UML platform was ready. The BioUML platform can be easily updated by uploading new modules to it. In 2009 Alexander Kel and Fedor Kolpakov have worked out an idea of outsourcing new modules for BioUML platform from third-party developers. This could make this platform a real leader in the biomedical data analysis software market as the number of applications now could be increased greatly via the crowdsourcing strategy, Biosoft has started a project of developing such a platform and thanks to the Skolkovo Foundation, which invested 5 mln. rubles by a minigrant in 2012 to this project, the BioUML platform is now being prepared for crowdsourcing.

In 2012 a new idea came to the founders of Biosoft. They decided not only to make an information platform for biomedical data analysis, they had an idea of opening a real science services online exchange market. Any scientific organization (CRO or an academic institute - it doesn't matter) could register on the Biosoft web site and hang out their services list. The services and companies could then be set up in a certain order by the staff of Biosoft project and later on a client could find any scientific service he needs. Moreover, Biosoft could provide an unprecedented approach of handling a turnkey approach to drug development by simply gathering all the drug discovery stages into one continuous process. Biosoft is currently looking for investments to bring this great idea to life.